Point72 Hong Kong’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-3,900
Closed -$2.69M 1339
2022
Q3
$2.69M Buy
3,900
+2,900
+290% +$1.83M 0.09% 268
2022
Q2
$591K Sell
1,000
-1,300
-57% -$845K 0.02% 668
2022
Q1
$1.61M Sell
2,300
-3,000
-57% -$1.9M 0.06% 380
2021
Q4
$3.35M Sell
5,300
-3,400
-39% -$2.09M 0.12% 195
2021
Q3
$5.26M Buy
8,700
+6,300
+263% +$3.91M 0.17% 116
2021
Q2
$1.34M Buy
+2,400
New +$1.22M 0.04% 598
2021
Q1
Sell
-500
Closed -$242K 2136
2020
Q4
$242K Buy
+500
New +$270K 0.01% 889

Other funds holding REGN

Point72 Hong Kong's REGN Position: Q3 2025 in Review

Point72 Hong Kong opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2025: 11,958 shares worth $6.72M. The stake represents 0.31% of the portfolio and ranks #63 among its holdings. This is a return to the name: Point72 Hong Kong previously reported a position in REGN as recently as Q4 2023.

Point72 Hong Kong first reported a position in REGN in Q4 2014 and has held it in 16 quarters since. The position peaked at $7.19M in Q4 2023. 1,245 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • Point72 Hong Kong held 11,958 shares of Regeneron Pharmaceuticals worth $6.72M as of Q3 2025.
  • Regeneron Pharmaceuticals was a new Point72 Hong Kong position in Q3 2025.
  • Regeneron Pharmaceuticals made up 0.31% of Point72 Hong Kong's portfolio in Q3 2025, its #63 holding.
  • Point72 Hong Kong first reported a position in Regeneron Pharmaceuticals in Q4 2014 and has held it in 16 quarters since.
  • Point72 Hong Kong's Regeneron Pharmaceuticals position peaked at $7.19M in Q4 2023.
  • 1,245 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Point72 Hong Kong's 13F filing for Q3 2025, filed 14 Nov 2025.